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Trial therapies for rare cancers are usually selected 
empirically and often fail during clinical testing. The poor 
efficiency and limited success of this process is hampered 
by a lack of accurate models with which to perform pre-
clinical studies, and small patient numbers that are likely 
to include distinct subtypes. These challenges are further 
compounded by increasing evidence that many cancers are 
heterogeneous diseases, composed of numerous different 
subtypes that are likely to require different therapies 
[1, 2]. Using a recently developed accurate model of a 
specific subtype of ependymoma, we have developed an 
approach to advance the efficiency and speed with which 
treatments for rarer cancers may be discovered, developed 
and prioritized [3].
Ependymomas are rare tumors of the brain and 
spinal cord that are incurable in up to 40% of cases. Like 
many human cancers, previous studies have indicated that 
ependymoma is a composed of different subtypes [1, 2]. 
To develop rational treatments of ependymoma, we are 
generating mouse models of each subtype in order to 
model human cancer heterogeneity during preclinical drug 
development [1]. Our first model faithfully recapitulates 
the histology and transcriptome of one form of human 
cerebral ependymoma (subtype-D): making it an attractive 
tool for developing treatments for this specific group of 
patients as well as understanding the signaling pathways 
important in sustaining the disease [1]. Further, since our 
models are generated from specific types of neural stem 
cells (NSCs), we are also able to test if candidate therapies 
are toxic to closely related normal cell types. Pre-clinical 
tools that allow measurement of drug efficacy as well as 
toxicity against stem and progenitor cells are especially 
important for developing treatments of children with 
cancer whose organ systems are immature [1]. 
Our report in the September 2011 issue of Cancer 
Cell describes an integrated, multiplatform in vitro and 
in vivo high throughput screen (HTS) of drug efficacy 
against our mouse model of subtype-D ependymoma, 
and concurrent assessment of toxicity against the parental 
normal embryonic cerebral NSC. This comprehensive 
approach identified several new candidate therapies for 
clinical development including tumor selective agents, as 
well as novel insights into the biology of ependymoma 
[3]. Through a combination of growth inhibition and 
kinome-wide binding assays, our studies demonstrated 
that inhibitors of the Insulin Growth Factor receptor 
signal pathway and centrosome cycle e.g., inhibitors of 
PLK1, are highly potent against subtype-D ependymoma. 
These kinases have not been previously implicated in the 
biology of ependymoma. 
In addition to identifying kinases important for 
maintaining ependymoma, our study emphasizes the 
value of HTS for rationally repurposing existing anti-
cancer drugs. Our HTS identified 5-Fluorouracil (5-FU) 
and two closely related compounds as highly selective 
and potent inhibitors of subtype-D ependymoma. 
Moreover,  this  potency  and  selectivity  was  confirmed 
in vivo. 5-FU has never been tested formally in patients 
with ependymoma. Indeed it is most unlikely that an 
early generation chemotherapeutic like 5-FU would ever 
be selected empirically for clinical trial. Consequently, 
we are now developing a clinical trial of 5-FU among 
children with ependymoma.
We are currently using the same methodology 
employed to produce subtype-D tumors to generate 
mouse models of the remaining eight ependymoma 
subtypes. Together with our integrated in vitro and in vivo 
screening approach, this battery of models should allow 
us to complete in months, numerous single and multidrug 
preclinical trials that would take decades to conduct in the 
clinic. Preclinical strategies such as these hold significant 
promise to identify and prioritize therapies for rational 
clinical trials among patients with specific subtypes of 
cancer.
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